Zelira Therapeutics Limited

ZLD

AU000000ZLD1

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 10:16:25 23/05/2024 am IST			5-day change	1st Jan Change
0.5 ^AUD	+8.70%		+2.04%	-44.44%

05:23am	Zelira Therapeutics Receives Third-Tranche of Funding for HOPE Clinical Trials	MT
15/04	Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	MT

Zelda Therapeutics Limited Announces Transition of Harry Karelis to a Non-Executive Chairman Role

January 30, 2019 at 01:02 pm IST

Zelda Therapeutics Limited announced that Mr. Harry Karelis will transition to a Non-Executive Chairman role effective from 31 January 2019.

Latest news about Zelira Therapeutics Limited

Zelira Therapeutics Receives Third-Tranche of Funding for HOPE Clinical Trials	08:53am	MT
Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	15/04	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	22/02	CI
Zelira Therapeutics Secures Grant Funding for Cannabinoid Product	08/01	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	15/11
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
Zelira Therapeutics Limited Announces Board Changes	31/23/31	CI
Transcript : Zelira Therapeutics Limited - Special Call	31/23/31
Zelira Therapeutics Bags Nearly AU$5 Million More Investment for HOPE SPV; Shares Rise 4%	22/23/22	MT
Zelira Therapeutics Limited announced that it expects to receive $22 million in funding	22/23/22	CI
Zelira Therapeutics Raises AU$1.8 Million Via Placement	15/23/15	MT
Zelira Therapeutics Halts Securities Trading Pending Capital Raising Announcement	13/23/13	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/23/28	CI
Transcript : Zelira Therapeutics Limited - Special Call	22/23/22
Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director	20/23/20	CI
Zelira Therapeutics Secures Nearly $9 Million Funding for US Clinical Trials of HOPE	15/23/15	MT
Zelira Therapeutics Secures R&D Tax Rebate	30/23/30	MT
Zelira Therapeutics Completes Drug Trial Patient Enrolment	21/22/21	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	17/22/17
Zelira Therapeutics Launches ZYRAYDI™ B2b Technology to Create Pharma-Grade Cannabis Capsules & Tablets for Global Markets	20/22/20	CI
Zelira Therapeutics Enrolls Two-Thirds of Patients for Diabetic Nerve Pain Medication	15/22/15	MT
Zelira Therapeutics Limited Completes Two-Thirds of Enrolment for Diabetic Nerve Pain Drug Trial	15/22/15	CI
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/22/31	CI
Zelira Therapeutics Limited Auditor Raises 'Going Concern' Doubt	31/22/31	CI
Zelira's Zenivol™, the First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany	21/22/21	CI

Chart Zelira Therapeutics Limited

Duration

Period

More charts

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZELIRA THERAPEUTICS LIMITED	-44.44%	34.65L
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.01%	11TCr
BIONTECH SE	-3.07%	2.47TCr
ARGENX SE	-1.08%	2.2TCr
GENMAB A/S	-5.34%	1.93TCr
BEIGENE, LTD.	-6.90%	1.76TCr
WUXI APPTEC CO., LTD.	-39.36%	1.73TCr
NEUROCRINE BIOSCIENCES, INC.	+5.82%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+33.05%	1.21TCr

Bio Therapeutic Drugs

Zelira Therapeutics Limited

Equities

ZLD

AU000000ZLD1

Biotechnology & Medical Research

Zelda Therapeutics Limited Announces Transition of Harry Karelis to a Non-Executive Chairman Role

Latest news about Zelira Therapeutics Limited

Chart Zelira Therapeutics Limited

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs